2021 BioBuzz Awards Finalists

Published on :

We’re excited to announce this year’s finalists for the second annual 2021 BioBuzz Awards. These awards celebrate the people and companies across our regional community and their efforts and accomplishments to impact human health and build a stronger biotech community.

Adaptive Phage Therapeutics Announces Licensing Agreement with the Walter Reed Army Institute of Research

Published on :

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has entered into a licensing agreement with The Walter Reed Army Institute of Research (WRAIR) to provide APT access to the Institute’s extensive phage database. The agreement with the United States Army is synergistic with APT’s ongoing partnership with the United States Navy, providing the company with access to the pre-eminent phage database of the United States military to treat critically ill patients.

Adaptive Phage Therapeutics Initiates Phase 1/2 Trial of PhageBank™ in Urinary Tract Infections

Published on :

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the first patient has been dosed in a Phase 1/2 study of bacteriophage therapy (PhageBank™) to evaluate the safety, tolerability, and efficacy of targeted, personalized, bacteriophage (“phage”) treatments in patients with urinary tract infection (UTI).

Adaptive Phage Therapeutics Announces $40.75 Million Series B Financing

Published on :

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company has closed a $40.75 million Series B investment round led by Deerfield Management Company. Also joining the Series B round are existing investor Mayo Clinic and an additional undisclosed institutional investor. Proceeds of this financing will be used to accelerate clinical development of PhageBank™ phage therapies as well as for general corporate purposes.